UK NHS Could Save £89 Million and Further the Fight Against Antimicrobial Resistance

A new study just published in the Journal of Medical Economics titled “Application of a simple point-of-care test to reduce UK healthcare costs and adverse events in outpatient acute respiratory infections” found that the FebriDx® test could save the United Kingdom’s healthcare system up to £89 million a year on unnecessary antibiotics, and further its efforts in the fight against antimicrobial resistance.

 

The FebriDx test has received HealthCanada approval, Saudi Arabia FDA clearance, Singapore HSA registration, Pakistan DRAP registration and is CE marked for sale in Europe. At this time, FebriDx has not received U.S. Food and Drug Administration (FDA) clearance and is not commercially available in the United States. For more information on FebriDx, visit febridx.com.

 

Media contact: Saranova, LLC • [email protected] • +1.941.928.9025

SEE ALSO
March 3, 2021

Lumos Diagnostics Announces Northern Diagnostics as Official Canadian Distribution Partner

Lumos Diagnostics announces a distribution partnership with Northern Diagnostics to bring the rapid FebriDx® test into Canada to facilitate the accurate diagnosis of viral and bacterial infections at the point of care.

Reach out to Lumos today to understand how we can deliver you a customized point-of-care diagnostic solution.